TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07595549: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)

Sponsor: Pfizer · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 954 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,550,280

Rescue Site Savings

+$7,637,328

Unlock Full NCT07595549 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07595549 Rescue Dossier →